Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Schnabel

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Therapeutic Advances in Chronic Disease|May 20, 2024
Real-world non-interventional post-authorization safety study of long-term use of burosumab in children and adolescents with X-linked hypophosphatemia: first interim analysisAnnemieke M Boot, Gema Ariceta, Signe Sparre Beck-Nielsen, et al.
Orphanet Journal of Rare Diseases|September 26, 2023
The International X-Linked Hypophosphatemia (XLH) Registry: first interim analysis of baseline demographic, genetic and clinical dataGema Ariceta, Signe Sparre Beck-Nielsen, Annemieke M Boot, et al.
Nature Genetics|July 26, 2003
Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcificationFrank Rutsch, Nico Ruf, Sucheta Vaingankar, et al.
Nature Reviews. Nephrology|February 5, 2025
Publisher Correction: Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemiaDieter Haffner, Francesco Emma, Lothar Seefried, et al.
Nature Reviews. Nephrology|January 15, 2025
Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemiaDieter Haffner, Francesco Emma, Lothar Seefried, et al.
Plos One|March 20, 2026
The lived experience of adolescents with X-linked hypophosphataemia treated with burosumab at end of skeletal growth: a mixed-methods analysisVrinda Saraff, Pedro Arango Sancho, Justine Bacchetta, et al.
Hormone Research in Paediatrics|January 8, 2026
Longitudinal Observation of Children With Achondroplasia: Findings From a Global Natural History Study (ACHieve)Ciara McDonnell, Hanne Buciek Hove, Melita Irving, et al.
The Journal of Clinical Endocrinology and Metabolism|April 25, 2023
Effects of Burosumab Treatment on Mineral Metabolism in Children and Adolescents With X-linked HypophosphatemiaAnnika Ewert, Mirko Rehberg, Karl Peter Schlingmann, et al.
Kidney International|October 26, 2024
Presentation and outcome in carriers of pathogenic variants in SLC34A1 and SLC34A3 encoding sodium-phosphate transporter NPT 2a and 2cMax Brunkhorst, Lena Brunkhorst, Helge Martens, et al.
European Journal of Endocrinology|June 23, 2026
Second interim analysis of the post-authorisation safety study (PASS) of burosumab in paediatric patients with X-linked hypophosphataemiaSigne Sparre Beck-Nielsen, Gema Ariceta, Annemieke M Boot, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Therapeutic Advances in Chronic Disease|May 20, 2024
Real-world non-interventional post-authorization safety study of long-term use of burosumab in children and adolescents with X-linked hypophosphatemia: first interim analysisAnnemieke M Boot, Gema Ariceta, Signe Sparre Beck-Nielsen, et al.
Orphanet Journal of Rare Diseases|September 26, 2023
The International X-Linked Hypophosphatemia (XLH) Registry: first interim analysis of baseline demographic, genetic and clinical dataGema Ariceta, Signe Sparre Beck-Nielsen, Annemieke M Boot, et al.
Nature Genetics|July 26, 2003
Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcificationFrank Rutsch, Nico Ruf, Sucheta Vaingankar, et al.
Nature Reviews. Nephrology|February 5, 2025
Publisher Correction: Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemiaDieter Haffner, Francesco Emma, Lothar Seefried, et al.
Nature Reviews. Nephrology|January 15, 2025
Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemiaDieter Haffner, Francesco Emma, Lothar Seefried, et al.
Plos One|March 20, 2026
The lived experience of adolescents with X-linked hypophosphataemia treated with burosumab at end of skeletal growth: a mixed-methods analysisVrinda Saraff, Pedro Arango Sancho, Justine Bacchetta, et al.
Hormone Research in Paediatrics|January 8, 2026
Longitudinal Observation of Children With Achondroplasia: Findings From a Global Natural History Study (ACHieve)Ciara McDonnell, Hanne Buciek Hove, Melita Irving, et al.
The Journal of Clinical Endocrinology and Metabolism|April 25, 2023
Effects of Burosumab Treatment on Mineral Metabolism in Children and Adolescents With X-linked HypophosphatemiaAnnika Ewert, Mirko Rehberg, Karl Peter Schlingmann, et al.
Kidney International|October 26, 2024
Presentation and outcome in carriers of pathogenic variants in SLC34A1 and SLC34A3 encoding sodium-phosphate transporter NPT 2a and 2cMax Brunkhorst, Lena Brunkhorst, Helge Martens, et al.
European Journal of Endocrinology|June 23, 2026
Second interim analysis of the post-authorisation safety study (PASS) of burosumab in paediatric patients with X-linked hypophosphataemiaSigne Sparre Beck-Nielsen, Gema Ariceta, Annemieke M Boot, et al.
Pageof 8